Structure Therapeutics: Unique Efficacy - Will Aleniglipron Become the Oral GLP-1 Breakthrough?

GLP-1 receptor agonists are among the world's top-selling classes of drugs – particularly due to their strong influence on weight loss. The body's own hormone GLP-1 works against both type-2 diabetes and obesity. The success story of such medications gained significant recognition through Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). Structure Therapeutics is now on the verge of becoming a direct competitor to the two major corporations. The latest research findings from December 8 led to a doubling of the stock price within...